ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia

Johnvesly Basappa\textsuperscript{a}, Mevlut Citirb, Qian Zhang\textsuperscript{e}, Hong Y. Wang\textsuperscript{e}, Xiaobin Liue, Olga Melnikova\textsuperscript{a}, Hafiz Yahya\textsuperscript{a}, Frank Steinb, Rainer Mullerb, Alexis Traynor-Kapland\textsuperscript{d}, Carsten Schultz\textsuperscript{b,c}, Mariusz A. Wasika\textsuperscript{a,e}, Andrzej Ptasznik\textsuperscript{a,*}

\textsuperscript{a} Fox Chase Cancer Center, Philadelphia, PA, USA
\textsuperscript{b} European Molecular Biology Laboratory (EMBL), 69117, Heidelberg, Germany
\textsuperscript{c} Oregon Health and Science University (OHSU), Portland, OR, USA
\textsuperscript{d} ATK Innovation, Analytics and Discovery and University of Washington, Seattle, WA, USA
\textsuperscript{e} University of Pennsylvania, Philadelphia, PA, USA

ARTICLE INFO

Keywords:
Biological sciences
Biochemistry
Cancer research
Health sciences
Metabolism
Cancer
Src
Lyn
PI3K
ACLY
Acetyl-CoA

ABSTRACT

A fundamental feature of tumor progression is reprogramming of metabolic pathways. ATP citrate lyase (ACLY) is a key metabolic enzyme that catalyzes the generation of Acetyl-CoA and is upregulated in cancer cells and required for their growth. The phosphoinositide 3-kinase (PI3K) and Src-family kinase (SFK) Lyn are constitutively activate in many cancers. We show here, for the first time, that both the substrate and product of PI3K, phosphatidylinositol-(4,5)-bisphosphate (PIP\textsubscript{2}) and phosphatidylinositol-(3,4,5)-trisphosphate (PIP\textsubscript{3}), respectively, bind to ACLY in Acute Myeloid Leukemia (AML) patient-derived, but not normal donor-derived cells. We demonstrate the binding of PIP\textsubscript{2} to the CoA-binding domain of ACLY and identify the six tyrosine residues of ACLY that are phosphorylated by Lyn. Three of them (Y682, Y252, Y227) can be also phosphorylated by Src and they are located in catalytic, citrate binding and ATP binding domains, respectively. PI3K and Lyn inhibitors reduce the ACLY enzyme activity, ACLY-mediated Acetyl-CoA synthesis, phospholipid synthesis, histone acetylation and cell growth. Thus, PIP\textsubscript{2}/PIP\textsubscript{3} binding and Src tyrosine kinases-mediated stimulation of ACLY links oncogenic pathways to Acetyl-CoA-dependent pro-growth and survival metabolic pathways in cancer cells. These results indicate a novel function for Lyn, as a regulator of Acetyl-CoA-mediated metabolic pathways.

1. Introduction

The most frequently activated signaling pathway in cancer is the phosphoinositide 3-kinase (PI3K) pathway (Traynor-Kaplan et al., 1988; Whitman et al., 1988; Goncalves et al., 2018). This is principally due to at least one, but more often multiple, genetic modifications in PI3K/PTEN and/or upstream activators such as \textit{RAS} subfamily proteins, receptor tyrosine kinases, and non-receptor tyrosine kinases including Src family kinases (SFK) that are common in all types of cancer (Goncalves et al., 2018). Two key signaling molecules common to these pathways are the phospholipids, P(4,5)\textsubscript{P\textsubscript{2}} and P(3,4,5)\textsubscript{P\textsubscript{3}}, whose alterations trigger cascades of pro-cancer responses such as cell proliferation, survival, adhesion and chemotaxis ((Traynor-Kaplan et al., 1988; Whitman et al., 1988; Goncalves et al., 2018). P(4,5)\textsubscript{P\textsubscript{2}} and P(3,4,5)\textsubscript{P\textsubscript{3}} couple to metabolic pathways through both AKT-dependent and AKT-independent mechanisms that can lead to tumor progression (Mahajan and Mahajan, 2012; Sivanand et al., 2017). Src was the first transforming protein (Rous, 1911) and protein tyrosine kinase (Hunter and Sefton., 1980) discovered. While the SFKs, particularly Lyn, are functionally and physically associated with PI3K (Ptasznik et al., 2002), and constitutively activated in acute myeloid leukemia (Dos Santos et al., 2008), chronic myeloid leukemia-blast crisis (Ptasznik et al., 2002, 2004), chronic lymphocytic leukemia (Contri et al., 2005), breast cancer (Tornillo et al., 2018), pancreatic cancer and fibrosis (Fu et al., 2006; Pham et al., 2016), glioblastoma (Stettner et al., 2005) and malignant melanoma (Zhang et al., 2019), Lyn's peculiar role in cancer cell metabolism remains to be elucidated.

A fundamental feature of tumor progression is reprogramming of metabolic pathways and gene regulation. ATP citrate lyase (ACLY) is a key enzyme for the synthesis of Acetyl-CoA, a critical precursor...
delivering acetyl groups for fatty acid/lipid/phospholipid synthesis and histone acetylation/gene regulation (Wellen et al., 2009; Cai et al., 2011; Zaidi et al., 2012; Sivanand et al., 2017). ACLY, and resulting lipid production and histone acetylation (Wellen et al., 2009), are upregulated in cancer (Cai et al., 2011; Zaidi et al., 2012). To examine the signaling and metabolic consequences of multiple pathogenic chromosomal aberrations and genetic mutations (Supplemental Information), we measured the direct binding of PIP2 and PIP3 to ACLY in AML patient- and normal donor-derived living marrow cells by the tri-functional PIP2 and PIP3 derivatives. We also performed several ACLY/PIP specificity binding assays with the ACLY purified peptides. To identify phosphorylated by Lyn/Src tyrosine sites of ACLY we used the phosphoproteomics analysis. We evaluated the effects of PI3K and Lyn inhibition on the ACLY-mediated Acetyl-CoA and phospholipid synthesis, histone acetylation and growth of HL-60 AML cells. We report here a molecular mechanism in which both the substrate and product of PI3K, PIP2 and PIP3, respectively, directly bind to the Lyn tyrosine kinase-phosphorylated ACLY. This couples oncogenic signaling events, through a tyrosine kinase-mediated mechanism, with the Acetyl-CoA synthesis, phospholipid metabolism, histone acetylation and cell proliferation in cancer.

2. Results

2.1. ACLY interacts with PIP2/PIP3 in patient-derived AML cells

Because AML patient-derived blasts, in contrast to non-malignant myeloid cells, express multiple mutated proteins that can alter PI3K signaling (Table S1), we examined whether the substrate and product of PI3K, PIP2 and PIP3, respectively, could bind to ACLY in these cells. Investigations of PIP2/PIP3 actions are often hampered by a lack of tools that can be used in living cells. However, it has recently been demonstrated that the novel tri-functional lipid probes (Höglinger et al., 2017; Laguerre and Schultz, 2018), including the phosphatidylinositol probes...
SRC kinase. After 36 h of transfection cells were subjected to DMSO or Dasatinib (2 μM) or BKM120 (2 μM) for 15 h and lysed in cell lysis buffer and followed the PIP2 protein tyrosine kinase-dependent and PI3-kinase-dependent manner. HEK293T cells were transfected with full length ACLY-HA alone or in co-transfection of active lysine-K to alanine-A (PIP2:K-A). For ACLY and PIP2 specificity sequence - peptide-2: ALTRKLIKK

The binding of the ACLY peptide-2 to PIP2 is decreased in the presence of Coenzyme A (PIP2:CoA) or with mutant ACLY peptide-2 with replacement of basic amino acid of PIP3 in living cells is several orders of magnitude lower than PIP2

immunoprecipitation and western blotting. The phospho-ACLY bound to PIP2 were quantified using the Cova PIP Specificity Plates (Figure 2D,E) and the ACLY mutant

Figure 2. PIP(4,5)P2 and PIP(3,4,5)P2 directly interact with the purified ACLY peptides and the ACLY full length protein (A-C) The ACLY full length protein binds to PIP(4,5)P2 and PIP(3,4,5)P2 in the membrane lipid strips assay. ACLY-HA tagged full length protein binding to membrane lipid strip (Echelon Biosciences) (Methods). The membranes have been spotted with 100 pmol of fifteen biologically important lipids (A). This assay shows that ACLY selectively interacts with the phosphorylated phosphoinositides (PIP, PIP2, PIP3), Phosphatidic Acid and Phosphatidylinerine, but not with phosphatidylinositol (PI) and nine other lipids (B). The membrane dots densitometry values were measured and used for the graph (C). The positive control is in Figure S6 (D-E) The ACLY peptide-2 (CoA-binding domain), but not the basal endogenous PIP3 levels were too low in these cells to be analyzed by immunofluorescence or blotting. It is well established that the abundance of PIP3 in living cells is several orders of magnitude lower than PIP2 (Methods). Therefore, we also probed the association of PIP(3,4,5)P2 with ACLY by binding the ACLY full length protein to membrane lipid strips (the membranes were spotted with 100pmol of fifteen biologically important lipids, see Methods) (Figure 2A). ACLY bound selectively to PIP, PIP2 and PIP3 in the membrane lipid strips binding assay (Figure 2B, C). In contrast, we detected no binding of ACLY to phosphatidylinositol (PI) and several other lipids, under the same conditions (Figure 2B,C). These data indicate that phosphorylated forms of phosphatidylinositol (PIP, PIP2 and PIP3), which are known to play important roles in cell signaling, can selectively interact with ACLY, in contrast to phosphati- dynositol (PI), which is their precursor and thus structurally very similar. It is consistent with our data obtained with the trifunctional PIP2 and PIP3 derivatives in living cancer cells (Figure 1B).

2.2. Identification of the PIP2 binding region of ACLY

Based on the PIP2 binding motif analysis and using the full length ACLY protein sequence, we predicted two potential PIP2 binding regions: the ATP-binding domain and the CoA-binding domain of ACLY. Therefore, we synthesized two different ACLY peptides containing either the ATP-binding domain or the CoA-binding domain sequences (Figure 6A and Table S3). The binding of these ACLY peptides to phospholipids on the Cova PIP Specificity Plates (Figure 2D,E) and the ACLY mutant important lipids, see Methods) (Figure 2A). ACLY bound selectively to PIP, PIP2 and PIP3 in the membrane lipid strips binding assay (Figure 2B, C). In contrast, we detected no binding of ACLY to phosphatidylinositol (PI) and several other lipids, under the same conditions (Figure 2B,C). These data indicate that phosphorylated forms of phosphatidylinositol (PIP, PIP2 and PIP3), which are known to play important roles in cell signaling, can selectively interact with ACLY, in contrast to phosphatidylinositol (PI), which is their precursor and thus structurally very similar. It is consistent with our data obtained with the trifunctional PIP2 and PIP3 derivatives in living cancer cells (Figure 1B).

2.2. Identification of the PIP2 binding region of ACLY

Based on the PIP2 binding motif analysis and using the full length ACLY protein sequence, we predicted two potential PIP2 binding regions: the ATP-binding domain and the CoA-binding domain of ACLY. Therefore, we synthesized two different ACLY peptides containing either the ATP-binding domain or the CoA-binding domain sequences (Figure 6A and Table S3). The binding of these ACLY peptides to phospholipids on the Cova PIP Specificity Plates (Figure 2D,E) and the ACLY mutant important lipids, see Methods) (Figure 2A). ACLY bound selectively to PIP, PIP2 and PIP3 in the membrane lipid strips binding assay (Figure 2B, C). In contrast, we detected no binding of ACLY to phosphatidylinositol (PI) and several other lipids, under the same conditions (Figure 2B,C). These data indicate that phosphorylated forms of phosphatidylinositol (PIP, PIP2 and PIP3), which are known to play important roles in cell signaling, can selectively interact with ACLY, in contrast to phosphatidylinositol (PI), which is their precursor and thus structurally very similar. It is consistent with our data obtained with the trifunctional PIP2 and PIP3 derivatives in living cancer cells (Figure 1B).

2.2. Identification of the PIP2 binding region of ACLY

Based on the PIP2 binding motif analysis and using the full length ACLY protein sequence, we predicted two potential PIP2 binding regions: the ATP-binding domain and the CoA-binding domain of ACLY. Therefore, we synthesized two different ACLY peptides containing either the ATP-binding domain or the CoA-binding domain sequences (Figure 6A and Table S3). The binding of these ACLY peptides to phospholipids on the Cova PIP Specificity Plates (Figure 2D,E) and the ACLY mutant important lipids, see Methods) (Figure 2A). ACLY bound selectively to PIP, PIP2 and PIP3 in the membrane lipid strips binding assay (Figure 2B, C). In contrast, we detected no binding of ACLY to phosphatidylinositol (PI) and several other lipids, under the same conditions (Figure 2B,C). These data indicate that phosphorylated forms of phosphatidylinositol (PIP, PIP2 and PIP3), which are known to play important roles in cell signaling, can selectively interact with ACLY, in contrast to phosphatidylinositol (PI), which is their precursor and thus structurally very similar. It is consistent with our data obtained with the trifunctional PIP2 and PIP3 derivatives in living cancer cells (Figure 1B).
experiment (Figure 2F) indicated that PI(4,5)P₂ selectively bound to the CoA-binding domain (peptide-2), but not to the ATP-binding domain (peptide-1) of ACLY. The differences detected by this binding assay between PI(4,5)P₂ and seven other control phospholipids were highly statistically significant. The ACLY peptide binding results on the CovA PIP Specificity Plates were consistent with our data obtained with five other assays: 1. the trifunctional PIP₂/PIP₃ derivatives binding assay in living cancer cells (Figure 1 A,B), 2. protein co-immunoprecipitation by Western blotting (Figure 1C), 3. protein co-localization by immunofluorescence (Figure 1D), 4. membrane lipid strips binding assay (Figure 2A-C), 5. the phospho-ACLY binding to PIP₂ in transfected cells (Figure 2G). Taken together, the mechanistically distinct experimental approaches and multiple data indicate consistently that ACLY directly binds to PIP₂ and PIP₃ and the specific association with PIP₂ is mediated through the ACLY CoA-binding domain (Figure 2E,F).

2.3. ACLY is phosphorylated on tyrosine residues by Lyn in AML

We observed that ACLY-mediated production of Acetyl-CoA is sensitive to Lyn tyrosine kinase inhibitor in AML (Figure 4 A-C). To determine whether Lyn plays a role in ACLY activation, we transfected kidney embryonic HEK293T cells either with HA-tagged ACLY alone or with HA-tagged ACLY and Src. Figure 3A shows that we could specifically precipitate 120-kDa strongly tyrosine phosphorylated ACLY protein with HA-conjugated agarose and that this phosphorylation only took place in cells co-transfected with Src. This observation was confirmed by in vitro tyrosine kinase assay on purified ACLY protein and Lyn immunoprecipitates from HL-60 AML cells. In the presence of active pY396-Lyn the ACLY was tyrosine phosphorylated and this process was sensitive to Lyn tyrosine kinase inhibitor (Figure 3B) (Methods). These findings show that SFK-dependent pathway, Lyn in AML cells, induces the ACLY activity in protein tyrosine kinase-dependent manner.

Figure 3. Lyn directly interacts and phosphorylates the tyrosine residues of ACLY (A) Src family kinase phosphorylate ACLY on the tyrosine residues. ACLY-HA and ACLY-HA + SRC transfected human HEK293T cells were lysed, precipitated with HA or IgG control antibody and blotted for p-ACLY (pan Tyrosine Y100), p-SRC (Y416) and HA. Cells transfected with Src showed remarkable induction of ACLY tyrosine phosphorylation and phosphorylated SRC (Y416) was present in ACLY-HA precipitates. The input lysate was also analyzed. Results are representative of two independent experiments (Methods) (B) LYN directly phosphorylates ACLY on the tyrosine residue. In vitro tyrosine kinase assay on ACLY (left panel): recombinant HA-tagged ACLY (non-phosphorylated form) was purified as described in the method section and was incubated with immunoprecipitated Lyn (from total lysates of HL-60 AML cells treated with DMSO or 500 nM Bafetinib for 16h) in in vitro kinase assay buffer and subsequently blotted with the indicated antibodies. The ACLY protein is phosphorylated on tyrosine residue only in the presence of active LYN (pY396) and this tyrosine phosphorylation of ACLY is prevented by the Lyn kinase inhibitor, Bafetinib. As indicated in the right panel, ACLY is present in Lyn immunoprecipitates in HL-60 AML cells (5% input) (C-D) Phosphoproteomics analysis of ACLY in vitro phosphorylated samples. Active recombinant Lyn or Src kinase directly phosphorylated purified His-tagged ACLY at tyrosine residues in an in vitro kinase assay (Methods). Phosphorylated Lyn (Y396) and Src (Y416) and also ACLY were detected by pan-phospho-Tyrosine antibody (pY100) (C). In vitro tyrosine phosphorylated ACLY samples were resolved on 10% Novex gels and stained with colloidal blue (D, left panel). The bands were excised and samples were evaluated by phosphoproteomics analysis. Phosphoproteomics Analysis (Methods) resulted in identification of novel Lyn kinase or Src kinase mediated tyrosine phosphorylation sites of ACLY. Sites on ACLY which are common in both Lyn and Src are highlighted in red (D, right panel). See also Figure 6A and Table S3. The full, non-adjusted western blot images are in Figure S7.
2.4. Identification of the tyrosine residues of ACLY that are phosphorylated by Lyn and/or Src

Next, we examined whether any of the tyrosine residues of ACLY could be directly phosphorylated by Src family kinases Lyn or Src. We performed in vitro tyrosine kinase assays on bacterially expressed and purified recombinant full length ACLY protein in the presence of active recombinant Lyn or Src and determined that active recombinant Lyn or Src directly phosphorylated purified ACLY at tyrosine residues (Figure 3C). The phosphoproteomics analysis of ACLY in vitro phosphorylated samples indicated that Lyn and Src directly phosphorylated ACLY on six and four tyrosine residues, respectively (Figure 3D). The three ACLY tyrosine residues, Y682, Y252, Y227, were common for Lyn and Src and were located in the catalytic domain, the citrate-binding domain and the ATP-binding domain, respectively (Figure 3D right panel, Figure 6A, Table S3).

2.5. ACLY enzyme activity and Acetyl-CoA production are inhibited by PI3K and LYN inhibitors in AML cells

To determine whether PI3K and Lyn activity could affect ACLY-mediated synthesis of Acetyl-CoA in AML, we treated HL-60 cells for 16 h with the specific Lyn inhibitor (Bafetinib) or two structurally and mechanistically distinct inhibitors of PI3K (LY294002 or BKM120), and then we measured ACLY enzyme activity and acetyl-CoA levels (Methods). As shown in Figure 4B, each of the three inhibitors significantly prevented the synthesis of Acetyl-CoA in AML cells. The corresponding control experiments indicated statistically significant inhibition of ACLY enzyme activity in these HL-60 cell lysates (Figure 4A). Coupled with the fact that PIP2 and PIP3 are directly associated with Lyn-phosphorylated ACLY (Figures 1, 2, and 3) and ACLY is a major enzyme for Acetyl-CoA synthesis (Cai et al., 2011; Zaidi et al., 2012; Sivanand et al., 2017) these findings strongly indicate that over-activated PI3K and Lyn in leukemia cells (Ptasznik et al., 2002, 2004; Dos Santos...
et al., 2008; Goncalves et al., 2018) stimulate the ACLY-mediated Acetyl-CoA production.

2.6. Growth of AML cells is strongly suppressed by Lyn, PI3K and ACLY inhibition

ACLY/Acetyl-CoA provides pro-growth and pro-survival signals to the cells, by providing acetyl groups that are required for histone acetylation at growth genes and fatty acids in phospholipid synthesis (Wellen et al., 2009; Cai et al., 2011; Zaidi et al., 2012; Migita et al., 2014). In the present study, we confirmed that the ACLY inhibitor BMS303141 inhibited within 72h growth of HL-60 AML cells with an IC50 of ~10-20uM (Figure 4E). This was lower than the effective doses reported in literature for ACLY-associated growth inhibition in other cells (Solomon et al., 2017). The similar pattern of growth inhibition within 72h was observed with the Lyn inhibitor and PI3K inhibitor (Figure 4 C,D). Thus, prolonged inhibition of Lyn, PI3K and ACLY can profoundly suppress AML cell growth. These results show that Lyn/PI3K and

![Figure 5](image-url)

**Figure 5.** Effect of Lyn and PI3K inhibitors on Fatty Acid composition of PI, PIP, and PIP2. HL-60 cells were treated with Lyn inhibitor (Bafetinib, BAF) or PI3K inhibitors (BKM120, BKM or LY294002, LY) or vehicle in the presence of 10% FBS in RPMI for 16 h for lipidomic analysis (Methods). The treatment with the inhibitors resulted in an overall decrease in levels of total PI/PIP/PIP2 (as compared to DMSO control - 100%) and the species of PIs with shorter fatty acid chains (32:0, 34:0) were most affected by the inhibitors, in a manner consistent with ACLY inhibition (see also explanation in Results). Control values were the means of 3 DMSO control samples against which values from individual treated samples were calculated. Data are means +/- SD, n = 3 (see additional results and statistics in Table S2).
ACLY/Acetyl-CoA provides pro-proliferation and pro-survival signals in AML cells.

2.7. H3K9 acetylation is prevented by PI3K and LYN inhibitors in AML cells

ACLY/Acetyl-CoA is required for histone acetylation by providing acetyl groups and initiates cell growth by promoting acetylation of histones specifically at growth genes (Wellen et al., 2009; Cai et al., 2011; Wan et al., 2017). The active oncogenic N-RAS and other oncogenes, that are expressed in our patient-derived primary AML cells and HL-60 AML cell line (Supplemental Information), can increase H3K9ac (Wan et al., 2017; Yi et al., 2018). Acetylation of H3K9 is particularly important, since it is present almost exclusively at growth genes and is highly correlated with active promoters of oncogenes (Wan et al., 2017; Yi et al., 2018). Since we observed that the PI3K and Lyn inhibitors prevented ACLY-mediated production of Acetyl-CoA (Figure 4), we examined whether these inhibitors could also suppress acetylation of H3K9 in AML cells. Indeed, Figure 4F shows that both Lyn tyrosine kinase and PI3K inhibitors almost totally blocked H3K9 acetylation in AML cells. These data (together with data in Figure 4 A-E) indicate that over-activated PI3K and Lyn in leukemia cells increase histone acetylation and gene activation through stimulating the synthesis of Acetyl-CoA.

2.8. Phosphoinositide fatty acid composition is altered by PI3K and Lyn inhibitors in AML cells in a manner consistent with ACLY inhibition

The production of fatty acids/phospholipids requires ACLY/Acetyl-CoA (Zaidi et al., 2012). Since we found that ACLY enzyme activity and production of Acetyl-CoA were blocked by PI3K and Lyn inhibitors (Figure 4 A,B), and PIP2/PIP3/Lyn were directly associated with ACLY (Figures 1, 2, and 3), we used mass spectrometric analysis to examine whether these inhibitors affected the fatty acid moieties of phosphoinositides in HL60 AML cells. Inhibitors suppressed PI, PIP and PIP2 formation, especially saturated and monounsaturated species with shorter fatty acid chains (Figure 5, Supplementary Table 2). Specifically, 32:0, 34:0 and 36:0 PI, PIP and PIP2 decreased most dramatically, according to the following order (32:0 > 34:0 > 36:0; PI > PIP > PIP2) (Figure 5, Table S2). This differential inhibition is consistent with ACLY/Acetyl-CoA inhibition since ACLY activity generates shorter chain fatty acids.
fatty acids first which are the precursors for longer chain fatty acids (Migita et al., 2014). Thus, the inhibition remodeled the overall phosphoinositide fatty acid profile and reduced total levels of phosphoinositides. Both mechanistically distinct inhibitors of PI3K and the Lyn inhibitor dramatically reduced PI/PiP2/PiP3 synthesis in leukemia cells (Table S2). These findings indicate that over-activated PI3K and Lyn in leukemia cells (Ptasznik et al., 2002, 2004; Dos Santos et al., 2008; Goncalves et al., 2018) augment phosphoinositide synthesis (including PiP2) through activation of ALCY/Acetyl-CoA.

3. Discussion

We demonstrate here that ALCY, a key enzyme generating Acetyl-CoA, directly interacts with crucial signaling molecules, PiP2/PiP3 and Lyn, in cancer cells. We show that the direct binding of Lyn to ALCY and the tyrosine phosphorylation and enzymatic activity of ALCY, are mediated by Lyn tyrosine kinase activity (Figures 3A, B, C, 4 and 6). The direct binding of PiP2/PiP3 to ALCY and activation of ALCY are mediated by both Lyn and PI3K activity (Figures 2G, 4, 6). We identify the PiP2-binding region in the key CoA-binding domain of ALCY and the Lyn/Src-regulated tyrosine residues also in the critical domains of ALCY (the catalytic domain, citrate-binding domain and ATP-binding domain) (Figure 6A). These data indicate that over-activated Lyn/Src and Pi3K/PiP2/PiP3 in cancer cells can directly bind to and modify the ALCY enzyme activity and Acetyl-CoA synthesis (Figure 6B).

Based upon the responses described herein to the PI3K and Lyn inhibitors, and several Lyn/Ps/A LCY binding experiments, we postulate that Lyn directly activates ALCY through a tyrosine kinase phosphorylation-mediated mechanism. Further, we propose that ALCY is activated in parallel by Lyn and PI3K-PiP2/PIP3, both contributing to ALCY activation. This scenario is consistent with the mutational pattern of AML cells showing multiple pathogenic mutations in PI3K pathway-activating proteins, including oncogenic N-RAS, which is frequently found in AML cases (Supplemental Information, Table S1; Figure S1). Also Lyn is highly expressed and constitutively phosphorylated in most, if not all, AML cases, as opposed to normal hematopoietic progenitors (Dos Santos et al., 2008).

Our results also suggest that AKT is bypassed by Lyn and PiP2/PiP3 in AML cells. First, Lyn and PI3K inhibitors reduce the ALCY enzymatic activity, but the AKT inhibitor Capivarsitib does not significantly ALCY activity in HL-60 AML cells (Figure 4A). Also, PI3K and Lyn inhibitors do not reduce AKT-dependent serine-threonine phosphorylation of ALCY at S454 in HL-60 cells, a recognized site of AKT-mediated phosphorylation (Figure 4F) (Sivanand et al., 2017). Second, AKT is not a hit target of functional inhibitors of PiP2 and PiP3 in AML patient-derived cells (Figure 1A,B, Figure S2 and data not shown). Third, PiP2 and PiP3 directly bind to ALCY, as we demonstrate by several different approaches, both in living cell and in vitro cell-free systems (Figure 1A-D and 2). Notably, it is also known that a specific and strong inhibition of Lyn expression in AML cell lines and multiple AML patient samples using siRNA does not affect AKT phosphorylation (Dos Santos et al., 2008). Together, this demonstrates that AKT and PI3K/Lyn can operate independently of each other, as previously reported in other malignancies (Mahajan and Mahajan, 2012). These findings indicate that PiP2/PiP3 and Lyn couple directly to ALCY inducing its activity through a novel tyrosine kinase-dependent mechanism in AML cells and thus independent of AKT, which is a serine/threonine-specific kinase. We conclude that, in addition to well documented AKT-mediated pathways for ALCY activation (Sivanand et al., 2017), the additional tyrosine kinase-mediated pathway exists, as we demonstrate in this paper in NRAS-mutant positive AML primary samples and HL-60 AML cell line (Table S1; Figure S1).

In conclusion, our results demonstrate a pathway which is based on the SFKs/PI3K-mediated regulation of functions underlying cancer growth through modulation of ALCY/Acetyl-CoA-dependent activities such as fatty acid/phospholipid synthesis and histone acetylation. This signaling paradigm (Figure 6) provides a tyrosine kinase dependent mechanism coupling oncogenic signal transduction to alterations in key metabolic pathways in cancer.

Declarations

Author contribution statement

J. Basappa and A. Ptasznik: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

M. Citir: Conceived and designed the experiments; Performed the experiments.

Q. Zhang, H. Wang, X. Liu, O. Melnikov and H. Yahya: Performed the experiments.

F. Stein: Analyzed and interpreted the data.

R. Muller and C. Schulz: Contributed reagents, materials, analysis tools or data.

A. Traynor-Kaplan: Performed the experiments; Analyzed and interpreted the data.

M. Wasik: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.

Funding statement

A. Ptasznik was supported by the Fox Chase Cancer Center Institutional Cancer Research Fund. C. Schultz was supported by the National Institutes of Health (R01GM127631). M. Wasik was supported by the Daniel B. Allanoff Foundation and the Berman Family Fund.

Competing interest statement

The authors declare no conflict of interest.

Additional information

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.heliyon.2020.e03910.

Acknowledgements

Mass Spectrometry proteomics services were provided by the European Molecular Biology Laboratory (EMBL), Heidelberg, Germany and Quantitative Proteomics Resource Core at School of Medicine in University of Pennsylvania, Philadelphia, United States. We thank Dr. Jonathan Chernoff for his critical reading of our manuscript and his comments.

References

Cai, L., Sutter, B.M., Li, B., Tu, B.P., 2011. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol. Cell 42, 426–437.
Cao, S., Chung, S., Kim, S., Li, Z., Manor, D., Buck, M., 2019. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PiP2): membrane association, protein orientation, and function. J. Biol. Chem. 294, 7066-7084.
Choi, S., Chen, M., Gryns, V.L., Anderson, R.A., 2019. A nuclear phosphoinositide kinase complex regulates p53. Nat. Cell Biol. 21, 462–475.
Contris, A., Brunati, A.M., Trentin, L., Cabrelli, A., Miorin, M., Cesaro, L., Pinna, L.A., Zambello, R., Semenzato, G., Donella-Deana, A., 2005. Chronic lymphocytic leukemia B cells contain abnormal Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest. 115, 369–378.
Dos Santos, C., Demur, C., Bardet, V., Prade-Houdellier, N., Payrastre, B., Rècher, C., 2008. A critical role for Lyn in acute myeloid leukemia. Blood 111, 2269–2279.
Fu, Y., Zagoudian, R., Avraham, R., Avraham, H.K., 2006. CHK negatively regulates Lyn with signaling lipid phosphatidylinositol (4,5)-phosphate (PiP2): membrane association, protein orientation, and function. J. Biol. Chem. 294, 7066-7084.
M. Citir: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.
Huntner, T., Selton, B.M., 1980. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. U.S.A. 77, 1311–1315.

Laguerre, A., Schultz, C., 2018. Novel lipid tools and probes for biological investigations. Curr. Opin. Cell Biol. 53, 97–104.

Mahajan, K., Mahajan, N.P., 2012. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J. Cell. Physiol. 227, 3178–3184.

Migita, T., Okabe, S., Ieda, K., Igarashi, S., Sugawara, S., Tomida, A., Soga, T., Taguchi, R., Seimiya, H., 2014. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. Int. J. Canc. 135, 37–47.

Müller, R., Citir, M., Hauke, S., Schultz, C., 2020. Synthesis and cellular labeling of caged phosphatidylinositol derivatives. Chem. Eur J. 26, 384–389.

Pham, H., Birtolo, C., Chleda, C., Yang, W., Rodríguez, M.D., Liu, S.T., Gugliotta, G., Lewis, M.S., Girulli, V., Pandol, S.J., Ptasznik, A., 2016. Essential role of Lyn in fibrosis. Front. Physiol. 7, 387.

Ptasznik, A., Urbanowska, E., Chinta, S., Costa, M.A., Katz, R.A., Stanislaus, M.A., Demir, G., Linnekin, D., Pan, Z.K., Gewirtz, A.M., 2002. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J. Exp. Med. 196, 667–678.

Ptasznik, A., Nakata, Y., Kalota, A., Emerson, S.G., Gewirtz, A.M., 2004. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL(+) leukemia cells. Nat. Med. 11, 1187–1199.

Rous, P., 1911. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397–411.

Sivanand, S., Rhoaden, S., Jiang, Q., Lee, J.V., Benci, J., Zhang, J., Yuan, S., Viney, I., Zhao, S., Carrer, A., Bennett, M.J., Minn, A.J., Weljie, A.M., Greenberg, R.A., Wellen, K.E., 2017. Nuclear acetyl-CoA production by ACLY promotes homologous recombination. Mol. Cell 67, 252–265.

Solomon, L.A., Poddar, S., He, J., Jackson-Chornenki, N.L., Gibson, K., Zilio, R.G., Rhe, J., Dekoter, R.P., 2017. Coordination of myeloid differentiation with reduced cell cycle progression by PU.1 induction of MicroRNAs targeting cell cycle regulators and lipid anabolism. Mol. Cell Biol. 37, 1–17.

Stettner, M.R., Wang, W., Nabors, L.B., Bharara, S., Flynn, D.C., Grammer, J.R., Gillespie, G.T., Gladson, C.L., 2005. Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cells. Can. Res. 65, 5538–5543.

Tornillo, G., Knowlson, C., Kendrick, H., Cooke, J., Mirza, H., Aurrekoetxea-Rodrigue, I., Vivanco, M.D.M., Buckley, N.E., Grigoriadi, A., Smalley, M.J., 2018. Dual mechanisms of LYK kinase dysregulation drive aggressive behavior in breast cancer cells. Cell Rep. 25, 3674–3692.

Traynor-Kaplan, A.E., Harris, A.L., Thompson, B.L., Taylor, P., Sklar, L.A., 1988. An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature 332, 644–646.

Whitman, M., Downes, C.P., Keeler, M., Keller, T., Cantley, L., 1988. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332, 644–646.

Yi, S.J., Hwang, S.Y., Oh, M.J., Kim, Y.H., Ryu, H., Rhe, J., Chun, B.H., Kim, K., 2018. Oncogenic N-ras stimulates SRF-mediated transactivation via H3 acetylation at lysine 9. BioMed Res. Int. 2018, 1–9. Article ID 5473725.

Zaidi, N., Swinnen, J.V., Smans, K., 2012. ATP-citrate lyase: a key player in cancer metabolism. Can. Res. 72, 3709–3714.

Zhang, Q., Meng, X., Qin, G., Xue, X., Dang, N., 2019. Lyn kinase promotes the proliferation of malignant melanoma cells through inhibition of apoptosis and autophagy via the PI3K/Akt signaling pathway. J. Canc. 10, 1197–1208.